PRO: Dose Response Study of a Fermented Yogurt on the Immune System and Gut Health

Sponsor
Laval University (Other)
Overall Status
Completed
CT.gov ID
NCT00730626
Collaborator
Aliments ULTIMA Foods Inc. (Industry), McGill University (Other), TransBiothec (Other)
58
1
3
9
6.5

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the dose-response effect of a yogurt containing a combination of bifidobacterium Lactis (BB-12) and Lactobacillus Acidophilus (LA-5) and green tea extract on markers of the immune system and gut health in healthy subjects. We hypothesize that the response of the immune function will be dose-dependent of the probiotics found in the fermented yogurt.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Yogurt with 1X10E9 BB-12 and LA-5
  • Dietary Supplement: Yogurt with 1X10E10 BB-12 and LA-5
  • Dietary Supplement: Yogurt Placebo
N/A

Detailed Description

There is an increasing list of food containing probiotics on the market. Several studies have emphasized the health benefits of single probiotics, particularly on the immune system. However, it is unclear how a combination of two different probiotics complemented with green tea extract can beneficially modify markers of the immune.

The aim of this study is to determine the dose-response effect of a yogurt containing a combination of bifidobacterium lactis (BB-12) and Lactobacillus Acidophilus LA-5 and green tea extract on immune system in healthy subjects. More specifically, this randomized, parallel placebo controlled study will investigate the impact of increasing doses (109 and 1010) of these probiotics on phagocytosis activity, oxidative metabolism and on the antipneumococcics antibody specific serotype response S. pneumoniae vaccination. Finally, this study will also examine the effect of increasing dose of these probiotics on intestinal microflora and blood lipids.

Study Design

Study Type:
Interventional
Actual Enrollment :
58 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Dose Response Study of the Impact of a Yogurt Containing Bifidobacterium Lactis BB-12 and Lactobacillus Acidophilus LA-5 on the Immune System and Gut Health.
Study Start Date :
Aug 1, 2008
Actual Primary Completion Date :
Dec 1, 2008
Actual Study Completion Date :
May 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1

L.acidophilus and B.lactis (1x10E9 of each probiotics) with 40 mg of green the extract

Dietary Supplement: Yogurt with 1X10E9 BB-12 and LA-5
100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.

Experimental: 2

L.acidophilus and B.lactis (1x 10E10 of each probiotics) with 40 mg of green tea extract

Dietary Supplement: Yogurt with 1X10E10 BB-12 and LA-5
100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.

Placebo Comparator: 3

Placebo

Dietary Supplement: Yogurt Placebo
100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.

Outcome Measures

Primary Outcome Measures

  1. Phagocytosis activity and oxidative metabolism in phagocytes. [6 weeks after vaccination]

Secondary Outcome Measures

  1. antipneumococcics antibody specific serotype response to S. pneumoniae vaccination. [6 weeks after yogurt consumption and vaccination]

  2. Intestinal microflora characteristics. [4 weeks after yogurt consumption]

  3. Influence of blood lipids. [After 4 weeks and 10 weeks of yogurt consumption]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age between 18 to 55 years

  • Healthy individuals, non-smokers

  • BMI between 18 and 35 kg/m2

  • Stable weight (+/- 5kg) for 3 months before randomisation

  • Agree to receive a vaccine Pneumovax 23®

Exclusion Criteria:
  • Pregnant or lactating woman

  • Previous history of cardiovascular disease

  • Diabetes

  • Kidney or liver disease

  • Gastrointestinal disorders or diseases

  • Endocrine disorders or diseases

  • Allergy

  • Subjects taking hypolipidemic drugs, antidepressant, medication for high blood pressure, for inflammation or auto-immune diseases.

  • Subject who have receive antipneumococcics vaccine in the year before randomisation.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institute of Nutraceuticals and Functional Foods (INAF), Laval University Quebec Canada G1V 0A6

Sponsors and Collaborators

  • Laval University
  • Aliments ULTIMA Foods Inc.
  • McGill University
  • TransBiothec

Investigators

  • Principal Investigator: Benoît Lamarche, PhD, Institute of Nutraceuticals and Functional Foods (INAF), Laval University.
  • Study Director: Jacques Hébert, MD, Faculty of Medicine, Laval University.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00730626
Other Study ID Numbers:
  • INAF-119
First Posted:
Aug 8, 2008
Last Update Posted:
Jun 22, 2009
Last Verified:
Jun 1, 2009

Study Results

No Results Posted as of Jun 22, 2009